Iroko is growing a development pipeline with a strong emphasis on analgesics.

We identify proven pharmaceuticals whose value can be enhanced with the proprietary SoluMatrix™ nanotechnology platform. Then we progress development quickly and efficiently through a network of partners coordinated by our experienced management team.

Four of our lower-dose NSAID formulation projects are currently in the mid- to late-development phase.